{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:02Z","timestamp":1792896902308,"version":"4.5.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T00:00:00Z","timestamp":1412640000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0109799","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T17:57:13Z","timestamp":1412704633000},"page":"e109799","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":144,"title":["Pharmacologic Blockade of JAK1\/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect"],"prefix":"10.1371","volume":"9","author":[{"given":"Jaebok","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alahmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ritchey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,10,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbmt.2010.02.005","article-title":"NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor\/Leukemia Reaction","volume":"16","author":"JS Miller","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bmt.2009.328","article-title":"New perspectives on the biology of acute GVHD","volume":"45","author":"S Paczesny","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1182\/blood-2012-01-403196","article-title":"IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD","volume":"120","author":"J Choi","year":"2012","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"JW Tyner","year":"2010","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/13543771003709767","article-title":"Recent patents in the discovery of small molecule inhibitors of JAK3","volume":"20","author":"LJ Wilson","year":"2010","journal-title":"Expert Opin Ther Pat"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.4049\/jimmunol.173.6.3620","article-title":"Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation","volume":"173","author":"MP Rettig","year":"2004","journal-title":"J Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"J Choi","year":"2010","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2002-12-3779","article-title":"High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression","volume":"102","author":"P Westervelt","year":"2003","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth779","article-title":"Real-time imaging of ligand-induced IKK activation in intact cells and in living mice","volume":"2","author":"S Gross","year":"2005","journal-title":"Nat Methods"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood.V88.8.3230.bloodjournal8883230","article-title":"An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin","volume":"88","author":"KR Cooke","year":"1996","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s002510050425","article-title":"Regulation of MHC class I and II gene transcription: differences and similarities","volume":"48","author":"PJ van den Elsen","year":"1998","journal-title":"Immunogenetics"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"K Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, et al.. (2014) Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood.","DOI":"10.1182\/blood-2013-12-543736"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2040620712461047","article-title":"Comprehensive review of JAK inhibitors in myeloproliferative neoplasms","volume":"4","author":"MB Sonbol","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2013-0198","article-title":"AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors","volume":"18","author":"ER Plimack","year":"2013","journal-title":"Oncologist"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"G Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"A Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","article-title":"The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors","volume":"16","author":"M Hedvat","year":"2009","journal-title":"Cancer Cell"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"JS Rawlings","year":"2004","journal-title":"J Cell Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1182\/blood.V91.9.3315","article-title":"Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion","volume":"91","author":"BR Dey","year":"1998","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2618-7","article-title":"Myeloid-derived suppressor cells in breast cancer","volume":"140","author":"J Markowitz","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1182\/blood-2010-06-287839","article-title":"Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13","volume":"116","author":"SL Highfill","year":"2010","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2009-11-252825","article-title":"Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses","volume":"116","author":"C Vogtenhuber","year":"2010","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1038\/bcj.2011.46","article-title":"The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma","volume":"1","author":"E Derenzini","year":"2011","journal-title":"Blood Cancer J"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","article-title":"Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo","volume":"20","author":"Y Hao","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","article-title":"Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism","volume":"171","author":"BR Blazar","year":"2003","journal-title":"J Immunol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2009-05-219402","article-title":"Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease","volume":"114","author":"T Yi","year":"2009","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1172\/JCI45284","article-title":"Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression","volume":"121","author":"LD Wartman","year":"2011","journal-title":"J Clin Invest"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1078-0432.CCR-12-2087","article-title":"The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia","volume":"19","author":"HJ Lee","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0109799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T13:36:45Z","timestamp":1598362605000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0109799"}},"subtitle":[],"editor":[{"given":"Vassiliki A.","family":"Boussiotis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,7]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0109799","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,7]]}}}